Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

NCT06972615 | Not Yet Recruiting Phase 2 DMC

• 1 other identifier: MK-3475-G14
• Study Type: interventional
• Target: 37
• Locations: 1 country
• Sites: 1

Brief Summary

interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC

Conditions

Non Muscle Invasive Bladder Cancer

Outcome Measures

Primary Outcomes (2)

• eficacy

  Complete Response rate

  3 months

• Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

  To evaluate safety and tolerability of systemic pembrolizumab in combination with intravesical gemcitabine/docetaxel

  1 year

Study Arms (1)

treatment

EXPERIMENTAL

intrravesical docetaxel plus gemcitabine and intravenous pembrolizumab

Drug: intravesical Chemotherapy docetaxel/gemcitabine

Interventions

intravesical Chemotherapy docetaxel/gemcitabine DRUG

intravesical quimiotherapy plus intravenous immunotherapy

Also known as: pembrolizumb

treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Be willing and able to provide documented informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research.
• Be ≥18 years of age on the day of signing informed consent.
• Have a histologically confirmed diagnosis of high-risk non-muscle invasive (T1, High Grade Ta and/or CIS) transitional cell carcinoma of the bladder. Subjects with tumors of mixed transitional/non-transitional cell histology are allowed, but transitional cell carcinoma must be the predominant histology. Subjects with predominant or exclusively non-transitional cell histology are not allowed. Confirmation of histology, grade and stage will be performed by central review and must be completed during the screening period and prior to enrollment.
• In subjects who have papillary tumors (Ta and T1), a complete TURBT must have been performed, as characterized by:Attainment of a visually complete resection of all papillary tumors (Ta and T1) 5- Have been treated with adequate BCG therapy and have developed high risk NMIBC that is unresponsive or exposed to BCG therapy.
• Adequate BCG therapy must include:
• An induction course with at least 5 out of 6 BCG instillations (adequate induction); and
• At least 7 out of 9 BCG instillations within 9 months of the first instillation of adequate induction therapy
• BCG unresponsive high risk NMIBC is defined as:
• Stage progression at 3 months (±4 weeks) despite adequate induction therapy (e.g., Ta to T1, or CIS to T1; note: adequate induction therapy only, defined above, is required in this case); or
• High grade T1 disease at the first evaluation after adequate BCG induction or
• Persistent high risk NMIBC at 6 months (±4 weeks) after adequate BCG; or
• Recurrent high risk NMIBC within 12 months of the last BCG instillation despite having received adequate BCG.
• BCG Exposed is defined as: having high-grade persistent (BCG resistant) or recurrent NMIBC within 24 months of the last BCG dose but not meeting the definition of BCG-unresponsive

You may not qualify if:

• \. Has muscle-invasive (i.e. T2, T3, T4) locally advanced non-resectable or metastatic urothelial carcinoma.
• \. Has concurrent extra-vesical (i.e. urethra, ureter or renal pelvis) non-muscle-invasive transitional cell carcinoma of the urothelium.
• \. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
• \. Has undergone any intervening intravesical chemotherapy or immunotherapy from the time of most recent cystoscopy/ transurethral resection of bladder tumor to starting trial treatment. (Note: A single dose of intravesical treatment given as part of the most recent cystoscopy/ transurethral resection of bladder tumor, during the screening period, such as with chemotherapy as per local/regional practices, is acceptable.)
• \. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Cycle 1, Day 1 or who has not recovered (ie, ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent

Sponsors & Collaborators

• BLATAM: lead

Study Sites (1)

BLATAM

CABA, 1123, Argentina

Location

Related Links

• Related Info

MeSH Terms

Conditions

Non-Muscle Invasive Bladder Neoplasms

Interventions

Gemcitabine

Condition Hierarchy (Ancestors)

Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Urinary Bladder Diseases; Urologic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Heterocyclic Compounds; Deoxycytidine; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring

Central Study Contacts

Gustavo M Villoldo, MD

CONTACT

+541156164207; gvilloldo@blatam.com

Martin O Angel, MD

CONTACT

+541149455892; mangel@blatam.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 18, 2025
• First Posted: May 15, 2025
• Study Start: April 1, 2026
• Primary Completion (Estimated): December 31, 2029
• Study Completion (Estimated): June 15, 2030
• Last Updated: February 17, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, ICF
• Time Frame: 1/jun/2025
• Access Criteria: data will be available on web site

Locations

AR (1)